+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Anti-Viral Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4787436
  • Report
  • May 2019
  • Region: Global
  • 114 pages
  • Mordor Intelligence
until Mar 31st 2020
1 of 4


  • AbbVie, Inc.
  • Cipla, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • MORE
Market Overview

The global anti-viral Therapeutics market is expected to register a CAGR of 6.0% over the forecast period, 2019 - 2024. North America dominates the market due to the growing prevalence of Hepatitis C & HIV infections, coupled with the presence of a huge patient pool suffering from virally infectious diseases.

In order to combat drug resistance, the combination of various anti-virals with different mechanisms of action is used. Combination antiviral therapy is the standard of care in HIV and hepatitis C virus infections and is likely to become increasingly used in other viral infections.

Anti-viral therapeutics are commercially available for a disease like influenza, hepatitis C, chicken pox, papilloma, and AIDS among others. There is increasing adoption of nucleoside and nucleotide analogues as first line anti-virals. Based on the current pipeline, many small-molecule based anti-viral drugs (like interferons and other similar small protein analogues) are expected to receive marketing approval.

Scope of the Report

The market for antiviral therapeutics has been considered according to the burden of the disease caused by viruses, at the global level. The anti-viral therapeutics market is essentially split into anti-viral drug markets for Herpes, Hepatitis, HIV, and Influenza, among other diseases. The market has also been segmented on the basis of distribution channel into hospital pharmacy, independent pharmacy, and online drug stores.

Key Market Trends

On the basis of Drug Type, HIV Antiviral Drugs Mainly Boost the Global Market

HIV is a major global public health issue. According to the 2018 UNAIDS Data, in 2017 approximately 37 million people were living with HIV. The global HIV prevalence among adults was estimated to be 0.8%. The vast majority of people living with HIV are located in low and middle-income countries, with an estimated 66% living in sub-Saharan Africa. However, the majority of HIV anti-viral consumption was exhibited in the North America region. Over the forecast period, the use of anti-virals in African countries is expected to increase multi-fold and propel the market growth.

North America Region Dominated the Market

North America dominated the global anti-viral therapeutics market, owing to the presence of well-established market players, and also due to the growing prevalence of HIV and Hepatitis C infections. Asia-Pacific is expected to grow tremendously during the forecast period owing to factors, such as the high prevalence of HIV infection, growing awareness regarding HIV infection, and increasing collaboration between public and private sectors.

North America market is primarily driven by factors such as the increasing occurrence of infectious disease, increasing geriatric population base, and growing healthcare awareness coupled with increasing healthcare expenditure in the region. However, there is a limitation to market growth in the region which include generic erosion and patent expiration of anti-viral drugs.

Competitive Landscape

The global anti-viral therapeutics market is a fast-growing market. The current market share is majorly controlled by a few major pharmaceutical and biotechnology companies. There is a limited number of antiviral products in the market, and a large percentage of these drugs are expected to lose exclusivity in the coming future. This will be marked by the entry of generic manufacturers, expansion of market size, and lowering of market concentration.
Note: Product cover images may vary from those shown
2 of 4


  • AbbVie, Inc.
  • Cipla, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Initiatives to Curb Viral Diseases by Public and Private Companies
4.2.2 Advancements in Molecular Biology Promoting Drug Development
4.2.3 Growing Burden of HIV Infection
4.2.4 Strong Pipeline for Antiviral Drugs
4.3 Market Restraints
4.3.1 Drugs going off-Patent
4.3.2 High Cost of Antiviral Drug Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 Drug Type
5.1.1 Herpes Antiviral Drugs
5.1.2 Hepatitis Antiviral Drugs
5.1.3 HIV Antiviral Drugs
5.1.4 Influenza Antiviral Drugs
5.1.5 Others Antiviral Drugs
5.2 Distribution Channel
5.2.1 Hospital Pharmacy
5.2.2 Independent Pharmacy and Drug Store
5.2.3 Online Pharmacy
5.3 Geography
5.3.1 North America US Canada Mexico
5.3.2 Europe Germany UK France Italy Spain Rest of Europe
5.3.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 AbbVie, Inc.
6.1.2 Bristol-Meyrs Squibb Company
6.1.3 Cipla, Inc.
6.1.4 F. Hoffmann-La Roche Ltd.
6.1.5 Gilead Sciences Inc
6.1.6 GlaxoSmithKline plc
6.1.7 Johnson & Johnson
6.1.8 Merck & Co., Inc.
6.1.9 Pfizer Inc.
6.1.10 Sanofi

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • AbbVie, Inc.
  • Bristol-Meyrs Squibb Company
  • Cipla, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi
Note: Product cover images may vary from those shown